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ORIGINAL ARTICLE
Six novel mutations including triple heterozygosity for
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are responsible for congenital factor X deficiency in patients
of Nepali and Indian origin
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Summary. Factor X (FX) deficiency is a rare (1 : 100000)
autosomal recessive disorder caused by heterogeneous muta-
tions in FX gene. We have studied the molecular basis this
disease in six Indian and one Nepali patients. Diagnosis was
confirmed by measuring the FX coagulant activity (FX: C)
using a PT based assay. Six of them had a FX: C of< 1% and
one patient had 24% coagulant activity. Mutations were
identified in all the seven patients. These included eight
(88.8%) missense and one frame-shift (11.2%) mutations of
which six were novel. Three of the novel mutations, a Phe31Ser
affecting Gla domain and 514delT and 516T fi G mutations
affectingCys132 in connecting regionwere identified in a triple
compound heterozygous state in a Nepali patient presenting
with a severe phenotype. Two other novel mutations,
Gly133Arg, may affect the disulphide bridge between Cys132-
Cys302 in the connecting region while Gly223Arg may perturb
the catalytic triad (His236,Asp282 andSer379). Theother novel
mutation, Ser354Arg, involves the replacement of a small-
buried residue by a large basic aminoacid and is likely to have
steric or electrostatic effects in the pocket involving Lys351-
Arg347-Lys414 that contributes to the core epitope of FXa for
binding to FVa. Three previously reported mutations,
Thr318Met; Gly323Ser; Gly366Ser were also identified. This
is the first report of the molecular basis of FX deficiency in
patients from the Indian subcontinent.
Keywords: conformation sensitive gel electrophoresis, factor X,
India.
Introduction
Human coagulation factor X (FX) is a vitamin K dependent
serine protease of central importance in blood coagulation [1].
FX gene is composed of eight exons, spanning 27 kb on
chromosome 13q34 [2]. Mutations in all these exons have been
shown to cause FX deficiency, a rare autosomal recessive
bleeding disorder affecting 1 : 1000000 in general population
[3–5]. It is more common with a eight- to 10-fold increased
frequency in populations (Iran, south India) practicing con-
sanguineous marriages [6]. The clinical features of this disorder
are among the most severe among patients with rare coagu-
lation defects [7] and typically include hemarthroses, muscle
hematomas, umbilical cord bleeding, gastrointestinal and
central nervous system (CNS) bleeds [8]. The molecular basis
of this disease is highly heterogeneous with a variety (approxi-
mately 65) of deletions, missense, frame shift and splice site
mutations reported [3,9,10] to date. In this report, we describe
for the first time, the molecular abnormalities found in the FX
gene of Indian patients.
Patients and methods
Patients
Six unrelated Indian patients and one from Nepal were
evaluated. Their diagnosis was based on prolonged prothrom-
bin time and activated partial thromboplastin time and their
FX coagulant activity (FX: C).
Factor X gene mutation analysis
Factor X gene was amplified by nine pairs of primers
(Table 1) designed by Primer3 software (http://frodo.wi.
mit.edu/cgi-bin/primer/primer3_www.cgi) (Date of last access
25 March 05). Mutations were screened by conformation
sensitive gel electrophoresis (CSGE) as previously described
Correspondence: Alok Srivastava, Department of Hematology,
Christian Medical College, Vellore, 632 004, India.
Tel.: +91 416 222 2102 Extn 2353; fax: +91 416 223 2035; e-mail:
aloks@cmcvellore.ac.in
Received 4 January 2005, accepted 4 February 2005
Journal of Thrombosis and Haemostasis, 3: 1482–1487
 2005 International Society on Thrombosis and Haemostasis
[11]. Abnormal CSGE patterns were sequenced by the Big Dye
Terminator cycle sequencing kit (Applied Biosystems, War-
rington, UK) on an ABI 310 genetic analyzer (PE Applied
Biosystems, Foster City, CA,USA).Mutation nomenclature in
the FX gene was used as previously described [12]. PCR
products from exon 2 and exon 6, were digested with restriction
enzymes (PCR-REA) DdeI (New England BioLabs, Hitchin,
UK) and SmaI (MBI Fermentas, St. Leon-Rot, Germany). All
the mutations identified were analyzed by the splice site
prediction program (http://www.fruitfly.org/seq_tools/splice.
html) (Date of last access 25 March 05) to predict changes in
RNA splicing. FX aminoacid sequences from 12 different
species and five related serine proteases were obtained from
SwissProt and Trembl databases (http://us.expasy.org/sprot/)
(Date of last access 25 March 05) using PSI-BLAST to study
the conservation of an aminoacid mutated by missense
change. Multiple sequence alignment was performed
with CLUSTALW (http://www.ebi.ac.uk/clustalw/). Missense
mutations were studied based on the normal type FXa three-
dimensional structure (PDB: 1hcg) [13]. Their potential effects
were modeled by SwissPdb Viewer [14]. The final images were
created by ViewerPro 4.2 software (http://www.accelrys.com).
Results
Patients
The clinical and hematological data of the patients evaluated in
this study is given in Table 2. The clinical features consisted of
easy bruisability (71%), epistaxis, hemarthroses, gum bleeding,
gastro-intestinal bleeding, CNS bleeding (28% each), ecchy-
moses, hematuria and umbilical cord bleeding (14% each).
Mutation analysis
The CSGE analysis followed by DNA sequencing identified
five polymorphisms and eight of nine disease causingmutations
(Table 2). CSGE failed to detect a T fi C transition predicting
a Phe31Ser mutation in PCR fragment/exon 2. This mutation
was identified by a complete sequencing of the FX gene. Of the
five different polymorphisms identified, four [IVS 1 ()52)
ins16 bp, IVS 2 ()17) T fi C, IVS 3 (+98) C fi A, IVS 7
(+33) A fi G] were novel while a C fi T transition for
Thr224Thr has been described [15]. Of the nine mutations,
eight (88.8%) were missense while one was a frame-shift
(11.2%). Six of these were novel mutations (Fig. 1).
Novel mutations
Triple compound heterozygous mutations were observed
in-patient BL-58 of Nepali origin with a severely reduced FX
activity. DNA sequencing revealed a heterozygous T fi C
transition in exon 2 predicting a Phe31Ser substitution in
Gla domain. Additionally, two different heterozygous
(514delT, 514T fi G) mutations in exon 6 were found
within a single codon (Cys132) in the connecting region
(Fig. 2). PCR-REA confirmed the paternal origin of
Phe31Ser substitution, while 514delT and 516T fi G muta-
tions affecting Cys132 was derived from a single allele from
the mother.
A G fi A transition in a homozygous state was responsible
for a Gly133Arg substitution in exon 6 to cause severe FX
deficiency (BL-17). Patient BL- 40 (FX: C < 1%) had a
homozygous G fi A mutation, predicting Gly223Arg in the
catalytic region. An A fi C homozygous transversion in exon
8 of FX gene resulted in Gly354Arg in the catalytic region
(BL-22).
Previously reported mutations
All the three previously reported mutations, namely
Thr318Met [16], Gly323Ser [10] and Gly366Ser [17] missense
mutations were present in exon 8 and affected the catalytic
region.
Table 1 Primers used for amplification of factor X gene. PCR for exonic fragments 3, 7, 8A, 8B was performed in a 25 lL volume containing 500 ng of
genomic DNA, 7.5–15 pmoles of each primer, 250 lM of each dNTPs, 0.87 units of Expand High Fidelity PCR system in supplied buffer-2 (Roche
Diagnostics, GmbH, Mannheim, Germany). For PCR fragments 1, 2, 4–6 amplification was performed in a 25 ll reaction volume containing 7.5–
15 pmoles of each primer in a 1X concentration of a ready reaction mix (ABgene, Epsom, UK) containing 75 mM Tris HCl (pH 8.8), 20 mM (NH)2SO4,
0.2 mM of each of dNTP, 0.01% (v/v) Tween 20 and 1.25 units of Thermoprime plus DNA polymerase. PCR conditions for each fragment are detailed
below. Following an initial denaturation at 94C for 5 min, 30 cycles of amplification was performed with denaturation at 94C for 40 s, annealing at
temperatures as mentioned below for 40 s and extension at 72C for 40 s. The final extension was at 72C for 5 min
Exon Forward primer (5¢–3¢) Reverse primer (5¢–3¢)
Amplicon
size (bp)
Forward and
reverse
primers (pmoles)
Final
concentration
of Mgcl2 (mM)
Annealing
temperature
(C)
1 GGGCCAGAGTGGATGTGTT ATGAGAGGGTTTCCCCAACT 329 7.5 1.5 58
2 CTGGATATGGCAAGGGACAT CCTGGATGGACGGAGCAG 343 7.5 1.5 58
3 TTCACAGATGCAGAAGATCTGA GAAACACCCTGAGGGAAAAA 350 15 1.5 48
4 CCAAAGAGGGGGAGTTGTTT TTAGGCGTTTTCACTTCTTCC 341 15 3.5 54.5
5 GATGTAGCTGGCACCCTTG GGCTCAGTCCTGTCCTCTTG 353 10 1.5 62
6 GCTATGGGGAGCCTCTCTCT GACAGGTGGTCTCTCCAGCA 345 7.5 1.5 58
7 CAGGAGACCGAAGAGGACAG TCAACCAGTGTTCCCAACAA 346 10 1.5 51
8A GATGTGCGAGAGCATGTCC CTTGAAGCGGGTGACGTG 476 7.5 1.5 57
8B GCTACGACACCAAGCAGGAG GTATCTGGGGAAAGGAATGC 475 15 1.5 52
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Discussion
We have identified the causative molecular defects in
seven unrelated patients with FX deficiency in India. Triple
heterozygosity (Phe31Ser, 514delT and 516T fi G) for novel
mutations was the cause for FX deficiency in one patient.
Phe31 is located in light chain of FX at the amino-terminal
Gla domain. Gla domain is involved in cell membrane and
calcium binding through its 11 c-carboxylated glutamic acid
residues [18]. Phe31 is an aromatic hydrophobic residue
conserved in 16 of 17 FX protein species examined (Table 3).
The substitution of this aromatic side chain by the hydroxylic
group of serine may open a cavity inside the hydrophobic core
to change the secondary structure or result in partial misfolding
of Gla domain. This could probably affect conformation-
dependent Gla domain binding to phospholipid membrane
[19] and normal activation [20]. Several other mutations
flanking Phe31 namely Glu26Asp [21] and Glu32Gln (Factor
X Tokyo) [22] have been shown to be pathognomic. The
presence of a topologically equivalentmutation in the FIX gene
[23] – Phe32Ser causing hemophilia B shows the importance of
this codon in Gla domain.
The 514delT and 516T fi G mutations occur in a single
codon Cys132. Cys132 is disulphide bonded to Cys302. This
links residues Ile125 to Arg139 of light chain of both FX and
FXa to their heavy chain [4]. The combinatorial effect of these
two mutations at codon 132 creates a glycine at this position
and a frame shift leading to TGA at residue 226 in catalytic
region. As a consequence, there could be destabilization of
heavy and light chain disulphide-bridge with a truncated
protein of 226 aminoacids, formed.
Gly133Argmutation was detected in a patient with FX: C of
< 1%. Gly133 is a highly conserved (Table 3) and small
aminoacid present in a hydrogen bonded turn in the connecting
region. This aminoacid is present in a hydrophobic environ-
ment (solvent accessibility – 0) [5]. The replacement of this
residue by Arg133 may place the larger side chain and polar
basic chemical groups of arginine to make additional hydrogen
bonds with Gln98, Ala112 and Phe392 (Fig. 3). This mutant
may probably destabilize disulphide linkage between the
adjoining residues Cys132 with Cys302. An Arg139Ser (Factor
X Kurayoshi) mutation around Gly133 has been postulated to
functionally affect FX interaction with FVIIIa and FVa [24].
The identification of two corresponding mutations in FIX [23],
namely a Gly133Arg and Gly133Glu to cause hemophilia B
suggests its importance in the connecting region of FX.
Interestingly, in our splice prediction analysis for this mutation
(517G fi A), a cryptic acceptor splice site between nucleotides
516tag-gaa521 is created (0.84, score for mutant FX) and the
actual splice site at nucleotide 503 (500cag-ggc506) getting a
concurrent score of 0.91. In the wild type DNA sequence the
efficiency of splicing at the physiological acceptor splice site is
0.95. This effect could not be confirmed at the RNA level
because of the non-availability of patient sample.
Gly223Arg corresponds to severe FX deficiency. Gly223 is
conserved in 14 of 17 FXor related proteases studied.Gly223 is
a very small aminoacid present in beta-strand C in serine
protease subdomain 1 [5], and in a hydrophobic environment
between Gly219 to Leu226 (solvent accessibility – 0). Its
replacement by Arg223 may cause the positive charge and the
1
2
3
4
5
6
7
8
Prepro
region
Gla domain
Linking region
EGF1-2
regions
Connection and
activation
region 
Catalytic
region
Phe31Ser*
514delT*
516T→ G*
Gly133Arg*
Gly223Arg*
Thr318Met
Gly323Ser
Ser354Arg*
Gly366Ser
Cys132FS*
Fig. 1. Schematic representation of factor X gene mutations identified
in this study. *Novel mutations, not reported previously in [3,9].
BL-58
Exon 6
NC NC BL-17
Fig. 2. Representative gel photograph of CSGE analysis for exon 6 of
factor X gene: patient PCR products were mixed with equal volume of
normal control (NC) PCR product and analyzed in a 12.5% CSGE gel.
The abnormal mobility of patient PCR product relative to a normal
control is shown by an arrow. Shown here are 514delT, 516T fi G
transversion mutations in patient BL-58 and a G fi A transition
predicting Gly133Arg aminoacid change in patient BL-17.
Molecular basis of FX deficiency in patients from Indian subcontinent 1485
 2005 International Society on Thrombosis and Haemostasis
larger side chain of arginine to impair the correct folding of this
protein or perturb the catalytic triad. The mutant also gains
hydrogen bonds with aminoacids in adjacent hydrophobic
(solvent accessibility – 0/1) beta strand B (Leu212), beta strand
D (Ile231) and beta strand H (Leu286). Topologically equiv-
alentmissensemutations causing FVII deficiency, aGly180Arg
[25] and FIX deficiency -Gly208Asp, Gly208Val, Gly208Ser
[23] suggest a critical role of Gly223 for FX activity. Apart
from mutations at codons 133 and 223 identified in this series,
mutations such as Gly20Arg (FX Santo Dominigo),
Gly114Arg (FX Ockero), Gly204Arg, Gly249Arg, Gly380Arg
[26] demonstrate the striking effect of Gly fi Arg substitutions
on FX protein stability.
Ser354Arg was detected in catalytic domain. Ser354 is
inaccessible (solvent accessibility – 0) in between the alpha helix
A2 (Arg347- Ser353) and a bend (Ser355-Phe356) in serine
protease subdomain 2 [5]. Replacement of Ser354 by Arginine
creates additional hydrogen bonds with Trp399, Tyr409 and
Ile411. Ser354 is close to Lys351. Lysine at codon 351 with
Arg347 and Lys414 is likely to contribute to the core epitope of
FXa for binding to FVa [27]. The mutation of a small-buried
residue by a large basic aminoacid is likely to have steric or
electrostatic effects on this pocket. Identification of a
Ser339Pro equivalent mutation in FIX [23] provides evidence
that mutations in this codon are severe enough to cause FX
deficiency.
Thr318Met (Factor X Roma) [16], Gly323Ser [10], Gly366-
Ser (Factor X Nagoya 2) [17] mutations identified here have
been reported previously in patients of Italian, British and
Japanese descent, respectively. Thr318Met represents an
example of a dysfunctional variant affecting FX activation.
Gly323Ser replaces a small amino acid with a considerably
larger one to yield a partially misfolded protein. Gly366Ser at
the primary substrate-binding pocket is predicted to compro-
mise substrate binding, consistent with loss of enzymatic
activity.
Two other large series on mutations causing FX deficiency
from Iran [5] and Europe [10] have been reported. Missense
mutations are the most frequent (88%) in this study as in the
earlier reports, 78% and 83%, respectively. The reported
absence of nonsense mutations in homozygosity in any of these
studies indicates that complete absence of FX is incompatible
with survival, in agreement with experimental data from
knockout mice [28]. None of the mutations in the present study
involved a CpG dinucleotide, the mutational hotspot found
frequently (66.6%) [10] in other studies. In contrast to previous
reports [10,29] most (n ¼ 6 of 7) of our patients were
homozygous for their mutations providing the clinical data
Table 3 Alignment of aminoacid sequence derived from factor X from different species and its related serine proteases. The conservation of aminoacids
in humans is shown in bold letters and their missense mutations are italicized. Aminoacid sequences were obtained from the SwissProt database [14]
with the accession numbers mentioned below. Multiple sequence alignment was performed with CLUSTALW (http://www.ebi.ac.uk/clustalw/)
Accession No. Protein
Codon
31 132 133 223 318 323 354 366
P00742 Human coagulation factor X precursor F C G G T G S G
Q28511 Rhesus macaque coagulation factor X F C – – T G S G
O88947 Mouse coagulation factor X precursor F C G G T G T G
Q63207 Rat factor X F C G G T G T G
O19045 Rabbit coagulation factor X precursor F C G G T G S G
P00743 Bovine coagulation factor X precursor F C G G T G S G
Q9GMD9 Duckbill platypus coagulation factor X F C G G A G S G
P81428 Troca coagulation factor X F C G G S G S G
P83370 Hopst coagulation factor X F C G G S G S G
P25155 Chick coagulation factor X precursor F C G G S G T G
AAH56804 Zebrafish coagulation factor X F C G G D G S G
Q804W9 Fugu coagulation factor X precursor F C G G D G T G
P00740 Human coagulation factor IX precursor F C G G S G T G
P08709 Human coagulation factor VII precursor F C G G F G S G
P22891 Human protein Z precursor F C G G S G L –
P04070 Human protein C precursor F C G A T G M G
P00734 Human Prothrombin precursor L T G A T G T G
Mutation S FS R R M S R S
A B
PRO120
CYS44LYS46
GLY45
TYR207
THR206
CYS122
PRO120
ARG45
RG45
TYR207
HR206
CYS122
CYS44
ALA24
GLN10
 PHE208
Fig. 3. Predicted effect of Gly133Arg (PDB: 1hcg numbering, B45)
mutation. Glycine at codon 133 is a very small aminoacid and is present in
a hydrogen bonded turn in the connecting region (A). This aminoacid is
present in a hydrophobic environment (solvent accessibility – 0). The
replacement of this residue by arginine at codon 133 may place the larger
side chain and polar basic chemical groups of arginine to make additional
hydrogen bonds with Gln98 (1hcg: B10), Ala112 (1hcg: B24), Phe392
(1hcg: A208) (B) thereby probably destabilizing the disulphide linkage
(Cys132-Cys302) that connects the heavy and light chains of FX and FXa.
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that will be a true reflection of their phenotype of some of these
novel mutations. However, a functional characterization
[27,30] of these mutants will be needed to demonstrate their
effect on FX biosynthesis and secretion.
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